Catalytic Asymmetric (3 + 3) Cycloaddition of Oxyallyl Zwitterions with α-Diazomethylphosphonates
作者:Yan Liu、Xian Peng、Rui She、Xin Zhou、Yungui Peng
DOI:10.1021/acs.orglett.1c02809
日期:2021.9.17
The unique structure of oxyallyls represents a significant challenge for their catalyticasymmetric applications. Herein, an unprecedented chiral imidodiphosphoric acid-catalytic enantioselective (3 + 3) cycloaddition between oxyallyl zwitterions generated in situ from α-haloketones and α-diazomethylphosphonates was developed. Pharmaceutically interesting chiral pyridazine-4(1H)-ones were obtained
reported that combines a cycloaddition reaction with a regioselective strain‐release process to afford diverse heterocyclic frameworks through bifunctional catalysis. The cooperation of hydrogen‐bonding network activation and a regiodivergent strain‐assisted effect is the key to promoting this complex chemical transformation, leading to the generation of two different ring systems in high yields with excellent
ORAL DOSAGE FORMS INCLUDING AN ANTIPLATELET AGENT AND AN ACID INHIBITOR
申请人:Cogentus Pharmaceuticals, Inc.
公开号:EP2007362A2
公开(公告)日:2008-12-31
JPH06135804A
申请人:——
公开号:JPH06135804A
公开(公告)日:1994-05-17
[EN] ORAL DOSAGE FORMS INCLUDING AN ANTIPLATELET AGENT AND AN ACID INHIBITOR<br/>[FR] FORMES DE DOSAGE ORALES INCLUANT UN INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE ET UN INHIBITEUR ACIDE
申请人:COGENTUS PHARMACEUTICALS INC
公开号:WO2007115305A2
公开(公告)日:2007-10-11
[EN] The present disclosure provides oral dosage forms comprising an antiplatelet agent and an acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an acid inhibitor. [FR] La présente invention concerne des formes de dosage orales contenant un inhibiteur de l'agrégation plaquettaire et un inhibiteur acide, de même que des procédés permettant de traiter des sujets avec un inhibiteur de l'agrégation plaquettaire et un inhibiteur acide.